443 related articles for article (PubMed ID: 36311748)
1. Effects of microenvironment in osteosarcoma on chemoresistance and the promise of immunotherapy as an osteosarcoma therapeutic modality.
Yu L; Zhang J; Li Y
Front Immunol; 2022; 13():871076. PubMed ID: 36311748
[TBL] [Abstract][Full Text] [Related]
2. Advances in Osteosarcoma.
Panez-Toro I; Muñoz-García J; Vargas-Franco JW; Renodon-Cornière A; Heymann MF; Lézot F; Heymann D
Curr Osteoporos Rep; 2023 Aug; 21(4):330-343. PubMed ID: 37329384
[TBL] [Abstract][Full Text] [Related]
3. The Fas/FasL Signaling Pathway: Its Role in the Metastatic Process and as a Target for Treating Osteosarcoma Lung Metastases.
Koshkina N; Yang Y; Kleinerman ES
Adv Exp Med Biol; 2020; 1258():177-187. PubMed ID: 32767242
[TBL] [Abstract][Full Text] [Related]
4. Modulation of immunosuppressive cells and noncoding RNAs as immunotherapy in osteosarcoma.
Xia Y; Wang D; Piao Y; Chen M; Wang D; Jiang Z; Liu B
Front Immunol; 2022; 13():1025532. PubMed ID: 36457998
[TBL] [Abstract][Full Text] [Related]
5. Tumor-associated macrophages in osteosarcoma.
Zhao Y; Zhang B; Zhang Q; Ma X; Feng H
J Zhejiang Univ Sci B; 2021 Nov; 22(11):885-892. PubMed ID: 34783219
[TBL] [Abstract][Full Text] [Related]
6. Reprograming the tumor immunologic microenvironment using neoadjuvant chemotherapy in osteosarcoma.
Deng C; Xu Y; Fu J; Zhu X; Chen H; Xu H; Wang G; Song Y; Song G; Lu J; Liu R; Tang Q; Huang W; Wang J
Cancer Sci; 2020 Jun; 111(6):1899-1909. PubMed ID: 32232912
[TBL] [Abstract][Full Text] [Related]
7. PAXX is a novel target to overcome resistance to doxorubicin and cisplatin in osteosarcoma.
Ma W; Yang L; Liu H; Chen P; Ren H; Ren P
Biochem Biophys Res Commun; 2020 Jan; 521(1):204-211. PubMed ID: 31640855
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs.
Chen C; Xie L; Ren T; Huang Y; Xu J; Guo W
Cancer Lett; 2021 Mar; 500():1-10. PubMed ID: 33359211
[TBL] [Abstract][Full Text] [Related]
9. Blocking miR-27a-3p sensitises Taxol resistant osteosarcoma cells through targeting Fbxw7.
Lu B; Feng Z; Fan B; Shi Y
Bull Cancer; 2021 Jun; 108(6):596-604. PubMed ID: 33863546
[TBL] [Abstract][Full Text] [Related]
10. The role of tumor-associated macrophages in osteosarcoma progression - therapeutic implications.
Huang Q; Liang X; Ren T; Huang Y; Zhang H; Yu Y; Chen C; Wang W; Niu J; Lou J; Guo W
Cell Oncol (Dordr); 2021 Jun; 44(3):525-539. PubMed ID: 33788151
[TBL] [Abstract][Full Text] [Related]
11. Targeting autophagy is a promising therapeutic strategy to overcome chemoresistance and reduce metastasis in osteosarcoma.
Liao YX; Yu HY; Lv JY; Cai YR; Liu F; He ZM; He SS
Int J Oncol; 2019 Dec; 55(6):1213-1222. PubMed ID: 31638211
[TBL] [Abstract][Full Text] [Related]
12. Metabolism and senescence in the immune microenvironment of osteosarcoma: focus on new therapeutic strategies.
Ying H; Li ZQ; Li MP; Liu WC
Front Endocrinol (Lausanne); 2023; 14():1217669. PubMed ID: 37497349
[TBL] [Abstract][Full Text] [Related]
13. Cracking the code: Deciphering the role of the tumor microenvironment in osteosarcoma metastasis.
Jin J; Cong J; Lei S; Zhang Q; Zhong X; Su Y; Lu M; Ma Y; Li Z; Wang L; Zhu N; Yang J
Int Immunopharmacol; 2023 Aug; 121():110422. PubMed ID: 37302370
[TBL] [Abstract][Full Text] [Related]
14. A comprehensive analysis of immune infiltration in the tumor microenvironment of osteosarcoma.
Yang H; Zhao L; Zhang Y; Li FF
Cancer Med; 2021 Aug; 10(16):5696-5711. PubMed ID: 34258887
[TBL] [Abstract][Full Text] [Related]
15. Trabectedin Overrides Osteosarcoma Differentiative Block and Reprograms the Tumor Immune Environment Enabling Effective Combination with Immune Checkpoint Inhibitors.
Ratti C; Botti L; Cancila V; Galvan S; Torselli I; Garofalo C; Manara MC; Bongiovanni L; Valenti CF; Burocchi A; Parenza M; Cappetti B; Sangaletti S; Tripodo C; Scotlandi K; Colombo MP; Chiodoni C
Clin Cancer Res; 2017 Sep; 23(17):5149-5161. PubMed ID: 28600479
[No Abstract] [Full Text] [Related]
16. miR-491 Inhibits Osteosarcoma Lung Metastasis and Chemoresistance by Targeting αB-crystallin.
Wang SN; Luo S; Liu C; Piao Z; Gou W; Wang Y; Guan W; Li Q; Zou H; Yang ZZ; Wang D; Wang Y; Xu M; Jin H; Xu CX
Mol Ther; 2017 Sep; 25(9):2140-2149. PubMed ID: 28648665
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the Tumor Microenvironment in Osteosarcoma Identifies Prognostic- and Immunotherapy-Relevant Gene Signatures.
Tan J; Feng X; Wu H; Yang B; Shi M; Xie C; Su Z; Li L; Luo M; Zuo Z; Zhu S; Yang J; Lin L
J Immunol Res; 2022; 2022():6568278. PubMed ID: 36065454
[TBL] [Abstract][Full Text] [Related]
18. Present Advances and Future Perspectives of Molecular Targeted Therapy for Osteosarcoma.
Shaikh AB; Li F; Li M; He B; He X; Chen G; Guo B; Li D; Jiang F; Dang L; Zheng S; Liang C; Liu J; Lu C; Liu B; Lu J; Wang L; Lu A; Zhang G
Int J Mol Sci; 2016 Apr; 17(4):506. PubMed ID: 27058531
[TBL] [Abstract][Full Text] [Related]
19. Altered pH gradient at the plasma membrane of osteosarcoma cells is a key mechanism of drug resistance.
Avnet S; Lemma S; Cortini M; Pellegrini P; Perut F; Zini N; Kusuzaki K; Chano T; Grisendi G; Dominici M; De Milito A; Baldini N
Oncotarget; 2016 Sep; 7(39):63408-63423. PubMed ID: 27566564
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant chemotherapy for osteosarcoma of the extremities with synchronous lung metastases: treatment with cisplatin, adriamycin and high dose of methotrexate and ifosfamide.
Bacci G; Briccoli A; Ferrari S; Saeter G; Donati D; Longhi A; Manfrini M; Bertoni F; Rimondini S; Monti C; Forni C
Oncol Rep; 2000; 7(2):339-46. PubMed ID: 10671683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
